Inclusion Criteria:

          -  Have completely resected (R0) NSCLC AJCC/UICC v. 8 stage IIA-IIIA and IIIB (N2 disease
             only) OR have NSCLC Stage IIA-IIIA, IIIB (N2 disease only) and are candidates for
             complete resection surgery

          -  Must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1
             (CTCAE v 4.03). Exception to this criterion: subjects with any grade of alopecia and
             grade 2 or less neuropathy are allowed to enter the study

          -  Have ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Have unresectable or metastatic disease, positive microscopic margins on the pathology
             report, and/or gross disease remaining at the time of surgery

          -  Have received neoadjuvant chemotherapy or neoadjuvant radiotherapy

          -  Presence or history of a malignant disease, other than the resected NSCLC, that has
             been diagnosed and/or required therapy within the past 3 years Exceptions to this
             exclusion include the following: completely resected basal cell and squamous cell skin
             cancers, completely resected carcinoma in situ of any type and hormonal maintenance
             for breast and prostate cancer > 3 years.

          -  Have a history of current diagnosis of cardiac disease

          -  Have uncontrolled diabetes

          -  Have known active or recurrent hepatic disorder including cirrhosis, hepatitis B and C
             (positive or indeterminate central laboratory results)

          -  Subjects must be evaluated for tuberculosis as per local treatment guidelines or
             clinical practice. Subjects with active tuberculosis are not eligible.

          -  Have suspected or proven immunocompromised state as described in the protocol

          -  Had Live and attenuated vaccination within 3 months prior to first dose of study drug
             (e.g. MMR, Yellow Fever, Rotavirus, Smallpox, etc.).